A comparison of the binding profiles of dextromethorphan, memantine, fluoxetine and amitriptyline: treatment of involuntary emotional expression disorder
about
Pseudobulbar affect: the spectrum of clinical presentations, etiologies and treatments.Clinical applications of hallucinogens: A review.Pseudobulbar affect: prevalence and management.Involvement of sigma-1 receptors in the antidepressant-like effects of dextromethorphan.Monoamine reuptake inhibitors in Parkinson's disease.Multiparametric Phenotypic Screening System for Profiling Bioactive Compounds Using Human Fetal Hippocampal Neural Stem/Progenitor Cells.Characterization of pulmonary sigma receptors by radioligand bindingPRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury.Evaluation of the reinforcing and subjective effects of heroin in combination with dextromethorphan and quinidineNext-generation sequencing of human opioid receptor genes based on a custom AmpliSeq™ library and ion torrent personal genome machineAn open-label multicenter study to assess the safety of dextromethorphan/quinidine in patients with pseudobulbar affect associated with a range of underlying neurological conditionsAcute cognitive effects of high doses of dextromethorphan relative to triazolam in humansHigh doses of dextromethorphan, an NMDA antagonist, produce effects similar to classic hallucinogensA study of potential pharmacokinetic and pharmacodynamic interactions between dextromethorphan/quinidine and memantine in healthy volunteers.Dextromethorphan/quinidine: in pseudobulbar affect.Dextromethorphan/quinidine: a review of its use in adults with pseudobulbar affect.An open-label study to assess safety, tolerability, and effectiveness of dextromethorphan/quinidine for pseudobulbar affect in dementia: PRISM II results.Treatment Resistant Depression with Loss of Antidepressant Response: Rapid-Acting Antidepressant Action of Dextromethorphan, A Possible Treatment Bridging Molecule.AVP-786 for the treatment of agitation in dementia of the Alzheimer's type.SSRI Augmentation by 5-Hydroxytryptophan Slow Release: Mouse Pharmacodynamic Proof of Concept.Anti-dyskinetic mechanisms of amantadine and dextromethorphan in the 6-OHDA rat model of Parkinson's disease: role of NMDA vs. 5-HT1A receptorsMemantine for the treatment of general neuropathic pain: a narrative review.Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease.Intravenous dextromethorphan/quinidine inhibits activity of dura-sensitive spinal trigeminal neurons in rats.New index of pain triggered by spinal activation of voltage-dependent sodium channels.Plasma dehydroepiandrosterone sulfate levels in patients with major depressive disorder correlate with remission during treatment with antidepressants.
P2860
Q34026748-9244E15D-700E-48FD-8C35-37D82B17BB67Q34535259-F23223B8-700D-422F-B0EC-0B1C8FA5255FQ34658447-33173B2B-2EE8-4F30-B3EB-82593167235AQ35108500-EF8E716F-19A6-4F2D-907E-64D6B6FF639EQ35165280-7F8E10EB-6041-484B-B38B-E67E1E17C125Q35738255-D8A4817C-5B80-4C1D-882B-7282306860F4Q35977409-496123C0-9CD6-483F-8CD6-6A15F6127228Q36045307-35438BA8-A0CB-4324-B3B4-DBFE32F5E7D6Q36100597-C8363F90-FC96-4C35-8993-743B2C20AFABQ36159969-24EDA5A9-E1F8-4817-BD56-CB137BB6AD07Q36551001-D29B5855-4EBE-4780-BA48-A674FAB2E7F0Q36582340-1030B0F6-C9D9-46F2-8F36-6B596E2F65FEQ36839080-1AFB7BC8-E203-420C-B000-D050149B73FFQ37021521-60749E80-AF7D-4F83-8D92-42C97D6ACEC4Q37863094-DD2E5493-2A07-4D91-ACA4-7819BCF90AFEQ38270903-9C5DE9FC-75D1-49F8-AB00-B0D28456C550Q38401900-EFDB0312-398E-4D0C-8322-46AF17AB04D3Q38979928-21D91456-5462-46FD-AA89-41C959FBD632Q39034436-EDBC5A0D-5628-4D07-A272-23DCA815EC37Q39955210-636F1529-278D-4DA3-92D0-9D7ECF2CE4ACQ42121362-FA7B3789-CA1C-4B2B-8DB3-96D87A60F429Q43061597-7654A20C-D3E8-4AB0-B504-BE3781AC19CEQ46280394-38889BBF-0683-4EBC-90EA-CE7301001AF8Q46550880-41104FF0-0EFE-41CD-82B3-1ABC4A40B5D6Q47999449-52C5E671-B595-4659-B7B9-7ED37A339B29Q48277387-596EE810-B3CB-4857-B206-A76F5C6552B7
P2860
A comparison of the binding profiles of dextromethorphan, memantine, fluoxetine and amitriptyline: treatment of involuntary emotional expression disorder
description
2007 nî lūn-bûn
@nan
2007 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
A comparison of the binding pr ...... emotional expression disorder
@ast
A comparison of the binding pr ...... emotional expression disorder
@en
A comparison of the binding pr ...... emotional expression disorder
@nl
type
label
A comparison of the binding pr ...... emotional expression disorder
@ast
A comparison of the binding pr ...... emotional expression disorder
@en
A comparison of the binding pr ...... emotional expression disorder
@nl
prefLabel
A comparison of the binding pr ...... emotional expression disorder
@ast
A comparison of the binding pr ...... emotional expression disorder
@en
A comparison of the binding pr ...... emotional expression disorder
@nl
P2093
P3181
P1476
A comparison of the binding pr ...... emotional expression disorder
@en
P2093
Ashleigh Keller
Julie G Frank
Linda L Werling
Samer J Nuwayhid
P304
P3181
P356
10.1016/J.EXPNEUROL.2007.06.013
P407
P577
2007-10-01T00:00:00Z